Psoriasis. Psoriasis vulgaris
Conditions
Interventions
oral Pioglitazone 30 mg daily for 12 weeks.
Treatment - Drugs
oral Pioglitazone 30 mg daily for 12 weeks
Sponsors
Research Council of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: new cases of plaque psoriasis which don’t received systematic treatment during last 3 months and for topical treatment last month, patients complete consent form and participate to study consciously. Exclusion criteria: patients who want to leave study deliberately, sensitive to pioglitazone or the same preparations, type one diabetes mellitus, pregnant or lactating women, below 18 years old, with severe hepatic problems (hepatitis, alcoholic or non alcoholic steatohepatitis, cirrhosis), severe cardiovascular disorders (NYHA CLASS III & IV), patients prevent pregnancy only by oral contraceptives, patients that have any of these following side effects during therapy: upper respiratory tract infections and sinusitis, edema and any indicative sign of heart failure, unwanted pregnancy, weight gain, anemia, leuckopenia, hematuria, jaundice and 3 times increment of hepatic enzymes (ALT), any symptom which make patients to leave the study. Patients who used any of these drugs (Oral contraceptives, Gatifloxacin ,Insulin ,sulfunamides ,sulfunylureas, Thioridazine , Gemfibrozil).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis severity. Timepoint: monthly untill the end of 12 weeks. Method of measurement: PASI standard method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect. Timepoint: monthly untill end of 12 weeks. Method of measurement: Standard evaluation method for this disease. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadis Yousefzadeh
Research center for skin disease and cutaneous leishmaniasis
Outcome results
None listed